Amarin Corporation plc
Amarin Corporation plc develops and commercializes cardiovascular disease treatments in the US, Europe, Canada, Lebanon, and the UAE. They offer VASCEPA, a prescription omega-3 fatty acid product for triglyceride reduction. Products are sold primarily to wholesalers and specialty pharmacies. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. Amarin was formerly known as Ethical Holdings plc and is headquartered in Dublin, Ireland.
Overview
Strengths
- Skin in the game: insiders own 37% of the shares, aligning management with shareholders.
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 1.4%) has been below its cost of capital of 7.0% in each of the last 7 years.
- Operating profit does not cover interest expense.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 5 of the last 7 years.
- Unstable profitability: operating margin ranged from -40% to 4% over the last 7 years, with operating losses in 6 of them.
Key Financial Data